MedTrace Logo

Effectiveness of Extra-corporeal Shockwave Diathermy in the Management of Upper Limb Function Patients With Stroke.

NCT07520032 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-09

No results posted yet for this study

Summary

Stroke is a leading cause of death and disability worldwide. A major complication of stroke is spasticity, marked by increased muscle tone and impaired movement. It affects majority stroke patients and complicates rehabilitation, affecting the upper limb function of survivors.

While traditional treatments like oral medications and botulinum toxin injections offer some relief, they have notable limitations, causing the need for novel, non-invasive approaches. Extracorporeal shock wave therapy (ESWT), which uses acoustic waves for regeneration and neuromodulation, has shown promise in reducing spasticity with minimal side effects, though its precise mechanisms and ideal protocols need further study. Current evidence supports ESWT's efficacy and safety, often matching established treatments, but gaps remain regarding standardized application and long-term functional outcomes, highlighting the need for more robust research.

Conditions

Interventions

OTHER

ESWT

Target muscles: biceps brachii, flexor carpi radialis, pronator teres, wrist and finger flexors. Protocol: 2000 shocks per muscle per session, energy flux density 0.03 mJ/mm², frequency 8 Hz, pressure \~0.2 MPa (2 bars).(1)

OTHER

Stretching

Sustained stretches held for 10 seconds, 3-5 repetitions per muscle group

OTHER

Mobility

Active and passive range of motion (ROM) exercises, 10-15 reps

OTHER

Strengthening

Isometric/ Isotonic exercises for antagonist muscles, 3 sets of 10-15 reps

OTHER

Functional training

Task-oriented activities ADLs. Eg: grasping, reaching, manipulation, 20-30 minutes per session

Sponsors & Collaborators

  • Gulf Medical University

    lead OTHER

Principal Investigators

  • Sharmila banu Ali, DPT/MPT · Thumbay Physical Therapy and Rehabilitation Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2026-05-30
Completion
2026-06-30

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07520032 on ClinicalTrials.gov